• Senseonics begins trial of 6-month glucose sensor in US

    4 days ago - By Healio

    Senseonics has enrolled its first U.S. patient in a clinical trial for its 180-day extended-wear continuous glucose monitoring sensor as part of a premarket application submission to the FDA, according to a press release from the company.
    The PROMISE study is designed to evaluate the safety and efficacy of the Eversense CGM system in people with diabetes and will include approximately 180 participants at up to 15 sites, according to the company. The Eversense XL sensor received a CE mark and is available in the European Union.
    The Eversense CGM consists of a fluorescence-based sensor, a smart
    Read more ...